Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Recommendation of “Reduce” from Brokerages

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) has been given a consensus recommendation of “Reduce” by the twelve research firms that are presently covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has given a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $8.20.

Several analysts have issued reports on the stock. JPMorgan Chase & Co. downgraded shares of Fulcrum Therapeutics from an “overweight” rating to an “underweight” rating in a research note on Wednesday, June 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Friday, July 17th.

Fulcrum Therapeutics Stock Performance

NASDAQ FULC opened at $3.69 on Friday. Fulcrum Therapeutics has a fifty-two week low of $2.83 and a fifty-two week high of $15.74. The company has a market cap of $281.93 million, a P/E ratio of -3.05 and a beta of 2.59. The business’s 50 day moving average price is $3.79 and its 200-day moving average price is $5.08.

Fulcrum Therapeutics (NASDAQ:FULC) last released its earnings results on Thursday, July 30th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.10). As a group, equities analysts predict that Fulcrum Therapeutics will post -0.6 EPS for the current year.

Hedge Funds Weigh In On Fulcrum Therapeutics

Institutional investors have recently made changes to their positions in the company. Summit Securities Group LLC purchased a new position in Fulcrum Therapeutics during the 1st quarter valued at about $53,000. The Manufacturers Life Insurance Company purchased a new position in Fulcrum Therapeutics in the second quarter worth $61,000. ProShare Advisors LLC purchased a new position in Fulcrum Therapeutics during the 4th quarter worth $116,000. Westshore Wealth LLC acquired a new position in shares of Fulcrum Therapeutics during the first quarter valued at about $130,000. Finally, Marquette Asset Management LLC acquired a new position in Fulcrum Therapeutics during the 2nd quarter valued at approximately $141,000. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for genetically driven diseases that affect skeletal muscle and other tissues. The company uses its FulcrumSeek drug-discovery platform to identify molecular targets and potential therapies for conditions in which the underlying biology is well characterized but treatment options remain limited.

Fulcrum’s lead product candidate is losmapimod, an investigational oral therapy being developed for facioscapulohumeral muscular dystrophy (FSHD), a rare inherited muscle-wasting disorder.